Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt

Fineline Cube Mar 4, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...

Company Drug

United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study

Fineline Cube Mar 4, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval...

Company Drug

CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors

Fineline Cube Mar 4, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...

Company Deals

AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal

Fineline Cube Mar 3, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...

Company Medical Device

Zeiss Group’s VISUMAX 800 with SMILE pro Software Approved by China’s NMPA

Fineline Cube Mar 3, 2025

Germany-based Zeiss Group, a specialist in optical systems and optoelectronic product manufacturing, announced that it...

Company Drug

Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials

Fineline Cube Mar 3, 2025

Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...

Company Drug

SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study

Fineline Cube Mar 3, 2025

SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...

Company Deals

Omron Healthcare and China Jo-Jo Drugstores Launch Atrial Fibrillation Screening Zone

Fineline Cube Mar 3, 2025

A joint effort between Japan-based Omron Healthcare and China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), a...

Company Deals

WORK Medical and Chartwell Med Partner on Investment Tools for Healthcare Projects

Fineline Cube Mar 3, 2025

WORK Medical Technology Group Ltd (NASDAQ: WOK), a medical consumables company based in Hangzhou, has...

Company Drug

Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda

Fineline Cube Mar 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...

Deals Drug

Eyebright Medtech Plans Private Placement to Expand Contact Lens Production

Fineline Cube Mar 3, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...

Company Drug

Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment

Fineline Cube Mar 3, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...

Company Deals

Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline

Fineline Cube Mar 3, 2025

Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...

Company Deals

Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics

Fineline Cube Mar 3, 2025

US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...

Company Drug

AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study

Fineline Cube Mar 3, 2025

AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...

Company Deals Digital

Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing

Fineline Cube Mar 3, 2025

Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co.,...

Company Deals

Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules

Fineline Cube Mar 3, 2025

China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...

Company Drug

CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Mar 3, 2025

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...

Company Deals

Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio

Fineline Cube Mar 3, 2025

Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...

Drug

CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment

Fineline Cube Mar 3, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...

Posts pagination

1 … 255 256 257 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.